Home › Liposarcoma › Massachusetts
Pag-aaral pangklinika para sa Liposarcoma sa Massachusetts
7 pag-aaral para sa Liposarcoma ang naghahanap ng mga kalahok sa mga site sa Massachusetts.
Mga Lungsod sa Massachusetts
Opisyal na teksto ng pag-aaral (English)
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Investigative Site, Boston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06881992Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06422806Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
- Dana-Farber/Harvard Cancer Center, Boston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT04031677Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT05711615STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT06975293NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Hanggang edad 30 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT06239272Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
- Brigham and Women's Hospital, Boston
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 15, 2026 · NCT07377747Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.